Source: Virtual Congress 2021 – Therapy of pulmonary hypertension



Rating:

Share or cite this content

Citations should be made in the following way:
A. Garcia (Madrid, Spain), I. Blanco (Madrid, Spain), R. Borras (Barcelona, Spain), M. Lopez-Meseguer (Barcelona, Spain), J. Domingo-Morera (Zaragoza, Spain), C. Martin-Ontiyuelo (Madrid, Spain), O. Tura (Madrid, Spain), I. Otero-Gonzalez (A Coruña, Spain), P. Escribano-Subías (Madrid, Spain), J. Barberà (Madrid, Spain). Predictors of response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension. 1921

Member's Comments

No comment yet.

Related content which might interest you: RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors Source: Eur Respir J, 50 (3) 1602425; 10.1183/13993003.02425-2016 Year: 2017 Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition Source: Eur Respir J 2013; 42: 869-870 Year: 2013 Comparison of acute hemodynamic effects of three different phosphodiesterase inhibitors in patients with pulmonary arterial hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 705s Year: 2004 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension Source: Eur Respir J 2007; 29: 220-221 Year: 2007 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 20s Year: 2003 HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 The use of combination therapy in pulmonary arterial hypertension: new developments Source: Eur Respir Rev 2009; 18: 148-153 Year: 2009 RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016 Phosphodiesterase 1 upregulation in pulmonary arterial hypertension – target for anti-remodeling therapy Source: Eur Respir J 2006; 28: Suppl. 50, 159s Year: 2006 Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Effect of PDE-5 inhibitor treatment in patients with interstitial lung disease and pulmonary hypertension Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011 Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 92-98 Year: 2009 Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004 Experience with pulmonary selective vasodilator treatment in COPD with severe pulmonary hypertension Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011 Prevention and partial reversal of monocrotaline-induced pulmonary arterial hypertension (PAH) by hsp90 inhibitors Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Pulmonary hypertension in COPD Source: Eur Respir Mon 2013; 59: 189-205 Year: 2013